Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin- dependent kinase 4/6 inhibitors (CDK4/6i): Real world data

Autor: Dedic Plavetic, Natalija, Čular, Katarina, Križić, Marija, Popovic, Marina, Plestina, Stjepko, Silovski, Tajana
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Popis: BC is the most common malignant disease and leading cancer- related cause of death in women. Despite significant achievements in the treatment, advanced BC (aBC) is still an incurable disease. HR+/HER2- subtype accounts for 70% of all BC. One of the most common mutations in BC is the PIK3CA gene mutation which can induce endocrine and chemo- resistance. There was no relevant difference in TTF between two groups. However, PIK3CA mutated subgroup had more aggressive clinical features - more often presented with bone marrow infiltration and de novo aBC, statistically relevant OR 5.158 and 2.323 respectively, which is related to lower quality of life and highlights the importance of treatment improvement for this subgroup of pts.
Databáze: OpenAIRE